anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Renal graft failure due to chronic rejection, also known as chronic allograft nephropathy, is one of the leading causes for repeat renal transplantation. Chronic rejection is characterized by progressive fibrosis and scarring. Renal biopsies of patients undergoing chronic rejection show greater expression of profibrotic cytokines, including TGF-beta and PDGF, than normal kidney tissue. Moreover, the cytokine activity of chronic rejection resembles that of other fibrosing renal diseases. Angiotensin converting enzyme inhibitors (ACEinh) and HMG-CoA reductase inhibitors have been shown to protect effectively against other types of fibrotic disease. These drugs may protect against fibrosis and preserve renal function in renal transplant patients with chronic rejection, in part by blocking activation of TGF-beta and PDGF. This study evaluates the impact of irbesartan (an AII-RB which acts similar to an ACEinh) and pravastatin on the clinical progression of chronic rejection and on the expression of TGF-beta, PDGF, and connective tissue genes in the chronically rejecting kidney.

Prior to intervention, patients undergo a transplant renal biopsy to: 1) confirm the presence of chronic renal allograft nephropathy and 2) quantify baseline mRNA levels for TGF-beta, PDGF, and selected cytokines and connective tissue components. Patients are randomized to 4 arms: Group 1 receives pravastatin placebo plus irbesartan placebo; Group 2 receives pravastatin plus irbesartan placebo; Group 3 receives pravastatin placebo plus irbesartan; and Group 4 receives pravastatin plus irbesartan. Pravastatin is administered at a dose of 20 mg/day. Irbesartan is initiated at 150 mg/day and is titred to 300 mg/day after 2 weeks. Patients are evaluated routinely for serum creatinine and potassium levels, blood pressure, and other markers of kidney function. In addition, they are monitored for toxicities and adverse events, particularly an early rise in serum creatinine or muscle enzyme changes. At Month 6, or when serum creatinine has risen above 5.0 mg/dl if that is earlier, a repeat transplant kidney biopsy is obtained to compare to baseline. Changes in chronic allograft nephropathy and cytokine mRNA levels are evaluated to determine any correlation between clinical effect and changes in activity of profibrotic pathways. Study endpoints are death or renal failure manifested by initiation of dialysis or retransplantation.
OBJECTIVES: Investigate how people with chronic obstructive pulmonary disease (COPD)-an example of a progressive, potentially fatal illness-are using digital technologies (DTs) to address illness experiences, outcomes and social connectedness.
MATERIALS AND METHODS: A transformative mixed methods study was conducted in Canada with people with COPD (n = 77) or with a progressive lung condition (n = 6). Stage-1 interviews (n = 7) informed the stage-2 survey. Survey responses (n = 80) facilitated the identification of participants for stage-3 interviews (n = 13). The interviews were thematically analyzed. Descriptive statistics were calculated for the survey. The integrative mixed method analysis involved mixing between and across the stages.
RESULTS: Most COPD participants (87.0%) used DTs. However, few participants frequently used DTs to self-manage COPD. People used DTs to seek online information about COPD symptoms and treatments, but lacked tailored information about illness progression. Few expressed interest in using DTs for self- monitoring and tracking. The regular use of DTs for intergenerational connections may facilitate leaving a legacy and passing on traditions and memories. Use of DTs for leisure activities provided opportunities for connecting socially and for respite, reminiscing, distraction and spontaneity.
DISCUSSION AND CONCLUSION: We advocate reconceptualizing consumer health technologies to prioritize quality of life for people with a progressive, potentially fatal illness. "Quality of life informatics" should focus on reducing stigma regarding illness and disability and taboo towards death, improving access to palliative care resources and encouraging experiences to support social, emotional and mental health. For DTs to support people with fatal, progressive illnesses, we must expand informatics strategies to quality of life.
PURPOSE:The titled pharmaceutical prepared by filling a chemical-impermeable vessel having an opening with a volatile chemical to form a space between the chemical and the opening, covering the whole vessel with a chemical-permeable resin, and capable of releasing the volatile chemical at a constant rate for a long term. CONSTITUTION:A pharmaceutical for prolonged release of a chemical prepared by filling the volatile chemical 4, e.g. a medicine such as nitroglycerin, methyl salicylate or menthol, a rust preventing agent having the volatility, antifungal agent or a deodorant, in the bottom of chemical-impermeable vessel 1, e.g. made of cellulose acetate or polyamide, having an opening 2 to form a space 3 between the chemical and the opening 2, and covering the vessel 1 with a chemical-permeable resin (layer) 5, e.g. a silicone resin, polyacrylic acid ester or gelatin. The resultant pharmaceutical is capable of releasing the chemical at substantially a constant rate by evaporating the volatile chemical filled in the vessel 1 first, saturating the space 3 in the vessel 1 with the vapor, diffusing the resultant vapor through the resin layer 5, and reaching the vapor to the surface to be applied, e.g. the skin.
The invention discloses a Yao-nationality medicine preparation for external use for preventing and treating woman puerperal fever and a preparing method thereof. The preparation is formed according to Yao-nationality theories and clinical practices. The preparation is prepared from 45-55 parts of schisandraceane, 25-35 parts of herb of glabrous sarcandra, 45-55 parts of treebine stem, 45-55 parts of buck grass, 55-65 parts of wang mucuna stem, 45-55 parts of smallflower embelia root and stem, 45-55 parts of ichnocarpus oliganthous, 45-55 parts of asiatic toddalia root, 25-35 parts of caulis spatholobi, 25-35 parts of caulis sinomenii, 25-35 parts of mountain spicy tree root and rhizome and 65-75 parts of giantleaf ardisia rhizome. When the Yao-nationality medicine preparation is used, the Yao-nationality medicine preparation is dissolved with warm water and used in a hip bath for external use. The Yao-nationality medicine preparation can achieve functions of dispelling wind, activating collaterals, eliminating damp, eliminating swell, dispersing stasis, relieving itching, removing putrefaction and promoting granulation, and has obvious effects for promoting woman puerperal fever. Clinical observation results show that: the preparation has obvious effects for treating and preventing the woman puerperal fever, and has a total effective rate of 84.3%. The preparation is convenient to carry, safe to use, definite in curative effects, mature in preparing process, controllable in quality and suitable for industrial production.
This is the group of 5 primary care practices that incurred the lowest amount of low-value back pain imaging based on claims data reports. This group will only receive the survey.
The intervention will last 8 weeks. As part of the intervention the participants (parents) will receive a notebook with weekly newsletters that discuss behavioral strategies for physical activity changes, note pages, listing of local parks, and age-appropriate physical activities that parents and young children can do together. The intervention group will also have individual weekly telephone meetings with a physical activity coach. The weekly meeting is expected to last approximately 30 minutes. During this meeting, participants will discuss that week's behavioral strategy to promote physical activity, report on the past week's physical activity goals, failures and successes, and set goals for the next week. Each week parents will be asked to set a goal to be physically active with their child and a goal to be physically active alone.
PURPOSE: Positively charged superparamagnetic iron oxide nano-particle, a contrasting agent using the same, and a method for manufacturing the same are provided to improve the reproducibility of the iron oxide nano-particles by modifying the surface of the iron oxide nano-particles into polymer with a plurality of carboxylic groups. CONSTITUTION: Positively charged superparamagnetic iron oxide nano-particles(10) are prepared. A polymer layer(12) is coated on the surfaces of the iron oxide nano-particles. Cationoid(14) is amide-bonded with the surface of the polymer layer. The polymer layer contains a plurality of carboxylic groups. A contrasting agent includes the superparamagnetic iron oxide nano-particles. A method for manufacturing the iron oxide nano-particles includes the following: the iron oxide nano-particles are prepared; the surfaces of the iron oxide nano-particles are coated with hydrophobic ligand; the hydrophobic ligand is substituted with polymer containing a plurality of carboxylic groups to form a hydrophilic polymer layer; and the carboxylic groups are reacted with amine-group containing the cationoid to form amide bonds.
BACKGROUND: Established as health insurance benefit in 2007, Specialized Palliative Home Care (SPHC) has been continuously expanded. At the same time, health policy initiatives intended to promote general outpatient palliative care. In comparison to urban centers, the development of palliative care networks in rural areas appears to be more difficult. In addition, there is an increasing shortage of family doctors in primary care. Family members play a key role in the home care for seriously ill patients. This paper therefore investigated the experiences of relatives with the end-of-life (EoL) care for family members with life-limiting chronic diseases in more rural regions. The aim was to determine aspects that, from the relatives' point of view, are essential for optimizing EoL care.
METHODS: Qualitative after-death interviews with relatives in two districts were conducted in the first six months of 2019, who were recruited by the deceased patients' family doctor. Relatives (age ≥18 years) of patients who died in 2018 were included. The interviews were digitally recorded, transcribed and analyzed using content analysis.
RESULTS: In the first half of 2019, 28 after-death interviews were conducted with 30 relatives (77% female, age: 32 to 83 years) from rural (n=8) and urban communities (n=22) in two Lower Saxonian counties. They were mostly in a partnership or parent-child relationship with the deceased person. The central categories and needs that emerged in the analysis were: (1) communication about dying and death, (2) information and enabling, (3) support of and relief for relatives, and (4) continuity and cooperation of the services involved in EoL care. The results underline the fact that family caregivers in particular find open communication, information to provide them with the confidence to act, recognizing and responding to support needs and continuity in the course helpful in coping with EoL care situations. Access problems to specialist medical care, deficiencies in care coordination and bureaucratic hurdles in the provision of medical aids proved to be an additional burden.
DISCUSSION: The results underline the importance of open communication and the integration of relatives into the care process for optimal care at the end of life. Close cooperation between the services involved and proactive support for relatives are essential, too, especially in rural areas where the challenges of accessing and coordinating care services are a major concern.
CONCLUSION: The identification and communication of complex problems, the needs of patients and their relatives and possible barriers to accessing care services are prerequisites for the timely initiation of palliative care measures and support for family caregivers. In addition to needs-based care structures, the optimization of EoL care in home settings requires cooperation and networking between professional stakeholders.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, oncology, and can be used for treatment of locally advanced and inoperable cancer of esophagus. For this purpose before beginning chemoradiation therapy argon plasma coagulation of tumour is performed. After that on 1-st, 8-th and 15-th day of the course intraluminal brachytherapy with high power dose 5-10 Curie with single dose 7 Gy is carried out. In addition, on 1-st, 8-th and 15-th day of the course intravenously taxoter 45 mg/m2 and carboplatin AUC 2 are introduced. After that teleirradiation SFD 1.8 Gy 5 fractions/week TFD 40-45 Gy is carried out. ^ EFFECT: method allows to increase efficiency of chemotherapeutic and radiation effect after preliminarily eliminated by argon plasma coagulation tumour stenosis of esophagus, succession of treatment stages allows to ensure maximal response of tumour, enhance degree of tumour regress and reduce probability of metastasis. ^ 2 ex
Obesity is a chronic disease of clinical treatment initially, but with precise surgical indications regulated by national and international health organizations. Among the surgical techniques, the gastric bypass Roux-en-Y is considered the "gold standard" for its efficiency and low morbidity and mortality. In gastric laparoscopic surgery it is necessary to move the liver in order to ensure adequate working space and a good view. Conventional laparoscopic retractors surgery are generally coarse, require an additional incision for its installation, or handling by an assistant during surgery and involve risk of liver injury. The objective of this study was to evaluate the efficacy of a flexible liver retractor in the exposure of the His angle in Roux-en-Y gastric bypass for morbid obesity. This was a prospective, controlled, open and comparative study, with 100 patients randomly divided into two groups (conventional and flexible retractor), with medical indication for bariatric surgery. Data were recorded during surgery in both groups for comparison of the two hepatic retraction techniques.
Planned daily doses range from 5 mg/day to 30 mg/day for 3 weeks. Weekly doses up to 75 mg/week for 3 weeks.
Described herein is a cohort engine that generates a cohort of patients with respect to a selected key patient record. The cohort engine receives, via a first user interface (UI), a key patient record. A patient-cohort generator is launched to determine an initial set of patient records that are to be included in the patient cohort. A second UI is configured to provide the initial set of patient records, where the second UI comprises at least three panes. Upon receiving, via the second UI, an input corresponding to at least one identifier being modified, an equation (i.e., query) is generated based on a combination of identifiers included in the second pane. An updated set of patient records is provided in a third pane of the second UI in response to the at least one identifier being modified.
Three manual brush gel applications followed by one tray gel application on Day 0. One manual brush application in the morning and one tray gel application in the evening on Days 1 through 6; total of 7-day study drug administration, 3.2 mg/mL C16G2 gel concentration.
The present invention is directed to a system for collecting, processing and providing access to healthcare treatment information. A first provider computer is provided for collecting and transmitting claim healthcare treatment information relating to a patient. The healthcare treatment information is communicated to a third party payer computer in communication with the first provider computer. A healthcare treatment information processing computer is provided in communication with the provider computer and the third party payer computer comprising computer software for collecting and processing the healthcare treatment information and adapted to display selected healthcare treatment information to a second provider. A method of collecting, processing and making available healthcare treatment information to providers is also provided. The method includes the steps of: entering healthcare treatment information relating to the treatment of a patient into a provider computer in communication with a claim intake system of a third party payer; communicating the healthcare treatment information to the third party payer; accessing the third party payer computer via a healthcare treatment information processing computer and extracting the healthcare treatment information relating to the treatment of the patient; and, providing access to the healthcare treatment information to a plurality of providers via a computer network.
This clinical trial utilized acupuncture as an adjunctive treatment for glaucoma patients. It is estimated a randomized clinical trial that 50 subjects will be enrolled and observed for 12 weeks to evaluate the clinical efficacy of acupuncture, providing a reference for future clinical treatment guidelines. Participants will be randomly divided into two groups: Ophthalmic Acupoint Treatment Group and Non-ophthalmological Acupoint Control Group. Participants in the treatment group will undergo acupuncture targeting ophthalmology-related acupuncture points, aiming to elicit the 'De Qi' sensation. Conversely, the control group will receive minimum acupuncture stimulation targeting non-ophthalmic acupuncture points without the intention of achieving the 'De Qi' sensation. Both groups will undergo acupuncture therapy once a week for a total of six sessions and will be observed for twelve weeks. On each visit, intraocular pressure, blood pressure, and heart rate will be assessed. Questionnaires of Glaucoma Symptom Scale (GSS) and The Glaucoma Quality of Life-15 (GQL-15) will be performed. The data of central corneal thickness, optical coherence tomography angiography, optical coherence tomography, visual field, and best-corrected visual acuity will be collected and analyzed before acupuncture and in the 12th week.
Particles for delivery of therapeutic agents are disclosed. In one embodiment, a particle for delivery of a therapeutic agent includes a hydrogel polymer matrix, a plurality of hydrophobic encapsulation sites within the hydrogel polymer matrix, and a hydrophobic therapeutic agent encapsulated within at least some of the encapsulation sites. The hydrogel polymer matrix may be hydrophilic. The hydrophobic encapsulation sites may comprise cyclodextrin conjugated to the hydrogel polymer matrix. The hydrogel polymer matrix comprises gelatin. The particle may have a diameter of 10 nm to 50 μm.
PURPOSE: The purpose of this study is to examine parent-reported ratings of temperament in toddlers with and without prelingual hearing loss.
METHOD: The parent-completed Early Childhood Behavior Questionnaire (ECBQ) was used to assess temperament in toddlers aged 18-36 months. Three dimensions of temperament were examined: surgency, negative affectivity, and effortful control. Analyses were conducted to (a) examine differences in temperament across toddlers with and without prelingual hearing loss; (b) examine possible associations between temperament, demographic, and communication factors; and (c) determine if the ECBQ is sensitive to differences in hearing, communication, and listening skills among toddlers with prelingual hearing loss.
RESULTS: The parent-completed ECBQ revealed that toddlers with prelingual hearing loss differed from their hearing peers on some but not all dimensions of temperament. Specifically, children with prelingual hearing loss were rated as displaying higher levels of surgency and lower levels of effortful control but comparable levels of negative affectivity when compared to their hearing peers. Regression analyses revealed that chronological age and communication strategy predicted scores of effortful control in toddlers with prelingual hearing loss, whereas chronological age alone predicted scores of effortful control in toddlers with hearing. Finally, the ECBQ appears to contain "listening" items that skew (lower) levels of effortful control in toddlers with prelingual hearing loss, such that only the group effect of higher levels of surgency remained after removing these "listening" items. Correlations between the original and our modified ECBQ (removing the "listening" items) revealed strong associations, reflective of high construct validity.
CONCLUSIONS: This was the first study to measure temperament in toddlers with prelingual hearing loss using the ECBQ. Our results revealed differences between children with and without prelingual hearing loss centering on the dimension of surgency. Examining differences in temperament during the toddler period of development may be particularly important and useful for predicting functional outcomes following prelingual hearing loss.
PURPOSE:To make it possible to collect blood plasma without dilution and to make priming before use unnecessary by constituting the title apparatus of a sampling needle, a sampling container, a plasma separator and a blood plasma sampling container and a blood transferring tube communicating with them. CONSTITUTION:When an anti-coagulant is filled in a blood sampling container 5, switching devices 11 and 12 are opened and the anti-coagulant is made to flow into a blood transferring tube 2. Switching devices 13 and 14 are closed and a blood sampling needle 21 is pierced into a vein of a blood donor and blood is collected in a collecting container 5 by actuating a vacuum function of a storing device 18 of a blood sampling container. The blood is then mixed with the anti-coagulant in the blood sampling container by actuating a stirring function of the storing device 18 of the blood sampling container. Then the switching device 12 is closed and the switching devices 13 and 14 are opened to pressurize the inside of the storing device 18 of the container and to send the blood into a blood plasma separator 7 through a blood transferring tube 6. The separated blood plasma flows into a blood plasma sampling container 10 through a blood plasma transferring tube 9. Thereafter, circuit switching devices 11 and 20 are opened and concentrated erythrocyte flowing out from a blood outlet 7b of the blood plasma separator 7 is returned in the vein through a blood transferring tube 8, a blood chamber 3 and the blood sampling needle 21.